stockportfolio.pro
4D Molecular Therapeutics, Inc. (FDMT)
Healthcare · Biotechnology · NasdaqGS
4D Molecular Therapeutics, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.99M | $13.61M | $18.04M | $3.13M | $20.72M | $37,000 | $85.21M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-49.31M | $-56.69M | $-71.32M | $-107.49M | $-100.84M | $-160.87M | $-140.11M |
| Net margin | -705.8% | -416.5% | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
Source: 4D Molecular Therapeutics, Inc. SEC filings (10-K).
Explore 7 years of 4D Molecular Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track FDMT in your portfolio →
4D Molecular Therapeutics, Inc. financial history by metric
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
4D Molecular Therapeutics, Inc. — frequently asked questions
What is 4D Molecular Therapeutics, Inc.'s revenue?
4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $85.21M for fiscal year 2025, up 230194.6% from the prior year, according to its SEC filings.
Is 4D Molecular Therapeutics, Inc. profitable?
No — FDMT reported a net loss of $-140.11M in fiscal 2025.
What is FDMT's P/E ratio?
4D Molecular Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is 4D Molecular Therapeutics, Inc. growing?
FDMT's revenue grew at roughly 44.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does 4D Molecular Therapeutics, Inc. have?
As of fiscal year 2025, FDMT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is 4D Molecular Therapeutics, Inc.'s market cap?
4D Molecular Therapeutics, Inc. (FDMT) has a market capitalization of about $442.78M, based on the latest data in our nightly-refreshed cache.
When does 4D Molecular Therapeutics, Inc.'s fiscal year end?
FDMT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from 4D Molecular Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.